Beta-thalassemia intermedia: An overview

Pediatric Annals

Volumn 37, Issue 5, 2008, Pages 322-328

  El Rassi, Fuad ^a   Cappellini, Maria Domenica ^b   Inati, Adlette ^c,d   Taher, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

^c Chronic Care Center Hazmieh   (Lebanon)

^d RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ERYTHROPOIETIN; HYDROXYUREA; IRON CHELATING AGENT; PLATELET DERIVED GROWTH FACTOR; SILDENAFIL;

BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; BONE MARROW TRANSPLANTATION; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; EXTRAMEDULLARY HEMATOPOIESIS; HEPATITIS C; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; LEG ULCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SPLENECTOMY; THROMBOPHILIA; THROMBOSIS;

EID: 45349099259     PISSN: 00904481     EISSN: None     Source Type: Journal    
DOI: 10.3928/00904481-20080501-06     Document Type: Review

References (22)

1. Taher A, Ismaeel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;27(1):12-20.
2. D.J. Weatherall. Thalassemia intermedia: cellular and molecular aspects. J Hematol. 2001;86(Suppl 1):186-188.
3. Guidelines for the Clinical Management of Thalassemia. Capellini MD, ed. Thalassemia International Federation; 2007; chapter 11. Reprinted with permission.
4. Capellini MD. The adult thalassemic patient. Hematol J. 2002;65-69.
5. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411- 3416.
6. Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest. 2005;127(5):1523-1530.
7. Origa R, Fiumana E, Gamberini MR, et al. Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann N Y Acad Sci. 2005;1054:451-456.
8. Chehal A, Aoun E, Koussa S, Skoury H, Koussa S, Taher A. Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis. Spine. 2003;28(13):E245-E249.
9. Castelli R, Graziadei G, Karimi M, Cappellini MD. Intrathoracic masses due to extramedullary hematopoiesis. Am J Med Sci. 2004;328(5):299-303.
10. Taher A, Ismae'el H, Mehio G, et al. The incidence of thromboembolic events among 8860 patients with thalassemia major and intermedia in the mediterranean area and Iran. Thromb Haemost. 2006;96(4):488-491.
11. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci MP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467-473.
12. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99(1):36-43.
13. Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in beta-thalassemia major and intermedia. Plast Reconstr Surg. 1982;69(2):320-325.
14. St. Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005;105(2):855-861.
15. Taher A, El Rassi F, Ismae'el H, Koussa S, Inati A. Correlation of serum ferritin levels and liver iron concentration determined by R2* MRI in patients with thalassemia intermedia. ASH Annual Meeting Abstracts. 2007;110:3818.
16. Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology Am Soc Hematol Educ Program. 2001:47-61.
17. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385.
18. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia - a promising therapy. Ann Hematol. 2005;84(7):441-446.
19. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380-385.
20. Perrine SP, Ginder GD, Faller DV,. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med. 1993;328(2):81-86.
21. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol. 2003;121(1):187-189.
22. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005;42(2 Suppl 1):S19-S21.